SecBot SecBot
PRESS-RELEASE ·Filed Apr 21, 2026

BIOA

BioAge Labs, Inc.
BULLISH
Impact 8/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The 85%+ hsCRP reduction is a strong biomarker signal for cardiovascular benefit, potentially positioning BGE-102 as a best-in-class NLRP3 inhibitor. With Phase 2 data expected by end-2026, traders should monitor trial initiation and enrollment trends as near-term catalysts. The lack of serious safety signals supports further development across multiple indications, increasing the asset's optionality.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$19.61
T+0 close · Apr 21, 2026 · via day close
Latest settled
+13.00%
T+60 · $22.16
Vs SPY
+6.10%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 21 $19.61entry
  2. T+1 · 7mo ago −6.37%α −7.39% · $18.36
  3. T+5 · 7mo ago −11.07%α −12.15% · $17.44
  4. T+20 · 6mo ago −21.77%α −26.69% · $15.34
  5. T+60 · 4mo ago +13.00%α +6.10% · $22.16
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioAge Labs announced positive Phase 1 results for BGE-102, its oral NLRP3 inhibitor, showing profound reductions in hsCRP and other inflammatory biomarkers in obese participants with elevated inflammation. The company plans to initiate Phase 2 proof-of-concept trials in cardiovascular risk and diabetic macular edema by mid-2026, with data expected by end-2026 and mid-2027, respectively.

Key Facts

  • BGE-102 achieved 85% median hsCRP reduction at 60 mg dose and 86% at 120 mg dose in participants with obesity and elevated inflammation
  • 87% of participants on 60 mg dose achieved normalized hsCRP (<2 mg/L) by Day 21
  • Drug was well tolerated with no serious adverse events or discontinuations
  • Phase 2 cardiovascular risk trial planned for initiation in first half of 2026, with data by end of year
  • Phase 1b/2a trial in diabetic macular edema to start mid-2026, data expected mid-2027

Financial Impact

Non-dilutive near-term catalyst with potential to revalue the stock based on upcoming clinical data readouts in 2026–2027

pipeline valueclinical progressR&D trajectory

Risk Factors

  • Phase 1 biomarker improvements may not translate into clinical outcomes in larger trials
  • Competition from other NLRP3 inhibitors in development

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3277765

Track record

11 reports on BIOA

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +4.03% at T+5 after the May 8, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $5.50 Now $5.22 −5.09% settles Nov 23
  2. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  3. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $5.34 to $5.55 Now $5.22 −2.25% ▲ +3.93% +1.34% vs SPY
  4. Jun 16, 202621w ago Press Release Neutral 3/10 Entry $20.49 to $22.32 Now $5.22 −74.52% ▲ +8.93% +11.16% vs SPY
  5. May 8, 202627w ago 8-K Bullish 7/10 Entry $17.99 to $18.72 Now $5.22 −70.98% ▲ +4.03% +2.57% vs SPY
  6. Apr 21, 202629w ago DEFA14A Neutral 3/10 Entry $18.36 to $17.14 Now $5.22 −71.57% ▼ −6.64% −6.70% vs SPY
  7. Apr 21, 202629w ago Press Release Bullish 8/10 Viewing Entry $19.61 to $17.44 Now $5.22 −73.38% ▼ −11.07% −12.15% vs SPY
  8. Apr 1, 202632w ago 144 Neutral 3/10 Entry $17.73 to $17.79 Now $5.22 −70.56% ▲ +0.34% −3.43% vs SPY
  9. Mar 24, 202633w ago Press Release Mixed 6/10 Entry $16.11 to $17.49 Now $5.22 −67.60% ▲ +8.57% +8.99% vs SPY
  10. Mar 2, 202637w ago Court Ruling Bullish 7/10 Entry $20.46 to $20.97 Now $5.22 −74.49% ▲ +2.49% +2.96% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens Wed (11h 11m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 21, 2026